viewParadigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals provides market update

Paradigm will be meeting with the US FDA in Feb 2020 for a pre-IND meeting among other things.

Paradigm Biopharmaceuticals Ltd - Paradigm Biopharmaceuticals provides market update
Paradigm will be attending a number of conferences in early 2020

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has provided the market with an update on its business today regarding the development of its flagship drug Zilosul.

Zilosul is the name for Paradigm’s flagship trial drug, injectable pentosan polysulfate sulfate (iPPS).

Paradigm is progressing through regulatory processes in multiple regions being Australia (TGA), the US (FDA), and Europe (EMA).

There are a number of clinical development and regulatory milestones upcoming including:

  • US pre-IND FDA meeting in February;
  • Proceeding with the provisional determination assessment process based on November TGA meeting;
  • Preparing FDA (US) and EMA (Europe) joint parallel advice application for submission to discuss the MPS Phase 2/3 Clinical Trial in March quarter;
  • Report update for Australian SAS program in June quarter; and
  • Commence EAP treatment program in January.

Presenting at upcoming conferences

Paradigm will also be attending the h JP Morgan Healthcare conference in San Francisco during January and the WORLD Symposium 2020 Lysosomal diseases research and conference in February.

The company has already secured a number of meetings with specialist US Biotech or healthcare Funds attending the San Francisco conference.

Furthermore, Paradigm has been selected to present a poster detailing outcomes from patient research advisory group informing its phase 2/3 clinical trial design at the WORLD Symposium.

US appointments

Paradigm has appointed Dr Donna Skerrett as its chief medical officer based in New York who has extensive experience with US FDA IND filing.

The company has also expanded its investor relations team hiring Mitch Marrow in the US and Simon White in Australia to start in January 2020.

Both have extensive financial industry experience and are high profile ex elite sportspeople.

Quick facts: Paradigm Biopharmaceuticals Ltd

Price: 2.9 AUD

Market: ASX
Market Cap: $651.74 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the...


2 min read